HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:
Sign In to gain access to subscriptions and/or personal tools.

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Request Reprints Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (22) Citing Articles via Google Scholar Google Scholar Articles by Modi, N. B. Articles by Gupta, S. Search for Related Content PubMed PubMed Citation Articles by Modi, N. B. Articles by Gupta, S. Social Bookmarking                         What's this?

Single- and Multiple-Dose Pharmacokinetics of Dapoxetine Hydrochloride, a Novel Agent for the Treatment of Premature Ejaculation

From ALZA Corporation, Mountain View, California.

Dapoxetine is a serotonin transporter inhibitor currently in development for the treatment of premature ejaculation. This randomized, 2-sequence, 2-treatment crossover study assessed the single- and multiple-dose pharmacokinetics of dapoxetine following once-daily administration of dapoxetine 30 mg and 60 mg to healthy male volunteers. Dapoxetine was rapidly absorbed following oral administration, with peak plasma concentrations reached approximately 1 hour after dosing; plasma concentrations after single doses of dapoxetine decreased rapidly to approximately 5% of peak concentrations by 24 hours. Elimination was biphasic, with an initial half-life of approximately 1.4 hours and a terminal half-life of approximately 20 hours. Dapoxetine showed time-invariant pharmacokinetics and dose proportionality between doses, and its pharmacokinetics was unaffected by multiple dosing. The pharmacokinetics of dapoxetine metabolites, desmethyldapoxetine and dapoxetine-N-oxide, was similarly unaffected by multiple dosing. There were no serious adverse events; the most commonly reported adverse events were diarrhea, dizziness, and nausea.

Key Words: Dapoxetine • pharmacokinetics • premature ejaculation

Address for reprints: Nishit B. Modi, ALZA Corporation, 1900 Charleston Road, Building M11-4A, Mountain View, CA 94043.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				N. B. Modi, R. Nath, P. Staehr, S. K. Gupta, J. W. Aquilina, and D. Rivas Pharmacokinetic, Pharmacodynamic, and Electrocardiographic Effects of Dapoxetine and Moxifloxacin Compared With Placebo in Healthy Adult Male Subjects J. Clin. Pharmacol., June 1, 2009; 49(6): 634 - 642. [Abstract] [Full Text] [PDF]

				N. B. Modi, S. Kell, J. Aquilina, and D. Rivas Effect of Dapoxetine on the Pharmacokinetics and Hemodynamic Effects of Tamsulosin in Men on a Stable Dose of Tamsulosin J. Clin. Pharmacol., December 1, 2008; 48(12): 1438 - 1450. [Abstract] [Full Text] [PDF]

				N. B. Modi, M. Dresser, D. Desai, C. Edgar, and K. Wesnes Dapoxetine Has No Pharmacokinetic or Cognitive Interactions With Ethanol in Healthy Male Volunteers J. Clin. Pharmacol., March 1, 2007; 47(3): 315 - 322. [Abstract] [Full Text] [PDF]

				M. J. Dresser, D. Kang, P. Staehr, S. Gidwani, C. Guo, J. P. Mulhall, and N. B. Modi Pharmacokinetics of dapoxetine, a new treatment for premature ejaculation: impact of age and effects of a high-fat meal. J. Clin. Pharmacol., September 1, 2006; 46(9): 1023 - 1029. [Abstract] [Full Text] [PDF]